Vanda Pharmaceuticals (VNDA) has three product candidates in clinical development for various central nervous system disorders. Lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder. VEC-162, a treatment of sleep and mood disorders, VSF-173, a compound for excessive sleepiness. Now in Phase 2 trial.

Announcements

May 1, 2007  

Expecting a net loss in fiscal 2007 to be between $110-$120 million, or approximately $(4.18)-$(4.56) per share. According to Reuters Estimates analysts were expecting the Company to report EPS of $(2.52) for fiscal 2007.

April 25, 2006 

Initiating a Phase 2 clinical trial of its product candidate VSF-173 in excessive sleepiness (ES). The randomized, double-blind, placebo-controlled study will investigate the safety and efficacy of three oral doses of VSF-173 for the treatment of induced excessive sleepiness. Candidates: Healthy volunteers. Number of candidates: 60. Gender : males and females. Primary endpoint: The difference from placebo on the Maintenance of Wakefulness Test (MWT), a standard measure of sleepiness.

January 19, 2007   

Phase 3 clinical trial results of iloperidone, an atypical antipsychotic for schizophrenia,  demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale (PANSS). Safety was consistent with what has been observed in previous iloperidone Phase 3 trials.

Iloperidone's efficacy and safety in patients with specific genetic profiles: Vanda had previously identified a polymorphism in a gene, occurring in approximately 70% of patients, hypothesized to be associated with the pathogenesis of schizophrenia, which appeared to correlate with iloperidone response. Iloperidone achieved statistical significance vs. placebo on the PANSS scale in these patients, with a magnitude of response greater than that seen in the overall iloperidone population.
 

November 2006  

VEC-162 demonstrated significant improvement in several parameters used to measure the efficacy of insomnia therapies, including reduced duration of wake after sleep onset, improved sleep efficiency and shortened time to persistent sleep.

FORWARD-LOOKING STATEMENT: Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled.It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-capand growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients.There can be no assurance that future events relating to the profiled company will occur as anticipated.The information contained herein is provided as an information service only.Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC")and/or the National Association of Securities Dealers ("NASD")We strongly recommend that you read theSEC advisory to investors concerning Internet Stock Fraud, which can be found at : http://www.sec.gov/consumer/cyberfr.htm.